How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,570 results for

NIH Stroke Scale

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Early effect of intra-arterial treatment in ischemic stroke on aphasia recovery in MR CLEAN. (Abstract)

with a proximal anterior circulation stroke were randomized to usual care plus IAT (<6 hours after stroke, mainly stent retrievers) or usual care alone. We estimated the effect of IAT on the shift on the NIH Stroke Scale (NIHSS) item language and the NIHSS item motor arm at 24 hours and 1 week after stroke with multivariable ordinal logistic regression as a common odds ratio, adjusted for prognostic variables (acOR). Differences between the effect of IAT on aphasia and on motor deficits were tested (...) Early effect of intra-arterial treatment in ischemic stroke on aphasia recovery in MR CLEAN. To investigate the effect of intra-arterial treatment (IAT) on early recovery from aphasia in acute ischemic stroke. We hypothesized that the early effect of IAT on aphasia is smaller than the effect on motor deficits.We included patients with aphasia from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), in which 500 patients

2016 Neurology Controlled trial quality: predicted high

182. Are all stroke patients eligible for fast alteplase treatment? An analysis of unavoidable delays. Full Text available with Trip Pro

of the Hurry Acute Stroke Treatment and Evaluation-2 (HASTE-2) project, we sought to identify patient and systems reasons associated with longer DNT.From June 2012 to June 2013 we collected data on DNT and potential reasons for delays from 102 consecutive patients presenting directly to the emergency department who were treated with alteplase within 4.5 hours of symptom onset.Mean age was 71 years, 56/113 (54%) were women, median NIH Stroke Scale score was 13, and median DNT was 53 minutes. Potential (...) Are all stroke patients eligible for fast alteplase treatment? An analysis of unavoidable delays. The National Quality Forum recently endorsed a performance measure for time to intravenous thrombolytic therapy which allows exclusions for circumstances in which fast alteplase treatment may not be possible. However, the frequency and impact of unavoidable patient reasons for long door-to-needle time (DNT), such as need for medical stabilization, are largely unknown in clinical practice. As part

2016 Academic Emergency Medicine

183. Changes in the cellular immune system and circulating inflammatory markers of stroke patients Full Text available with Trip Pro

) cells in stroke patients on days 1, 3, and 7. Serum levels of TNF-α, C-reactive protein (CRP), IL-4, IL-6, IL-10, IL-17, IL-23, and TGF-β increased, whereas serum level of IFN-γ decreased at all time points after stroke. Stroke patients with infection exhibited a similar tendency toward changes in some lymphocyte subpopulations and inflammatory markers as stroke patients without infection. After controlling for NIH Stroke Scale (NIHSS), we observed no differences in lymphocyte subpopulations between (...) Changes in the cellular immune system and circulating inflammatory markers of stroke patients This study was designed to investigate dynamic changes in the cellular immune system and circulating inflammatory markers after ischemic stroke. Blood was collected from 96 patients and 99 age-matched control subjects for detection of lymphocyte subpopulations and inflammatory markers. We observed decreases in B cells, Th cells, cytotoxic T cells, and NK cells and an increase in regulatory T (Treg

2016 Oncotarget

184. Post-IV thrombolytic headache and hemorrhagic transformation risk in acute ischemic stroke Full Text available with Trip Pro

, 59.5 ± 17.4 years vs 69.9 ± 15.5 years, p < 0.0001), and 53% of HP were men, compared to 49.2% of NHP (p = 0.537). Comorbid conditions did not differ between the 2 groups. There were no statistical differences between HP and NHP in admission NIH Stroke Scale (NIHSS) score (11.2 ± 5.7 vs 11.5 ± 5.5, p = 0.646), NIHSS score at 24 hours (6.5 ± 5.7 vs 7.4 ± 6.9, p = 0.466), NIHSS score at discharge (6.7 ± 10.1 vs 8.1 ± 11.6, p = 0.448), HT (12.7% vs 18.4%, p = 0.3), cervical artery dissection (4.7% vs (...) Post-IV thrombolytic headache and hemorrhagic transformation risk in acute ischemic stroke Background: Headache during or soon after administration of IV tissue plasminogen activator (tPA) in patients with acute ischemic stroke (AIS) is a concern for hemorrhagic transformation (HT). However, no data are available regarding the incidence of HT in these patients or the prognostic indication of these headaches. We examine the importance of tPA-associated headaches among AIS patients in terms of HT

2016 Neurology: Clinical Practice

185. ICAT: a simple score predicting critical care needs after thrombolysis in stroke patients Full Text available with Trip Pro

on strength of association.Seventy-two patients (24.8%) required critical care interventions. Black race (odds ratio [OR] 3.81, p=0.006), male sex (OR 3.79, p=0.008), systolic blood pressure (SBP; OR 1.45 per 10 mm Hg increase in SBP, p<0.001), and NIH stroke scale (NIHSS; OR 1.09 per 1 point increase in NIHSS, p=0.071) were independent predictors of critical care needs. The optimal model for score development, predicting critical care needs, achieved an AUC of 0.782 in the validation group. The score (...) ICAT: a simple score predicting critical care needs after thrombolysis in stroke patients Patients receiving intravenous thrombolysis (IVT) for acute ischemic stroke are at risk of developing complications, commonly necessitating admission to an intensive care unit (ICU). At present, most IVT is administered in the Emergency Department or in dedicated stroke units, but no evidence-based criteria exist that allow for early identification of patients at increased risk of developing ICU needs

2016 Critical Care

186. Intravenous rtPA versus mechanical thrombectomy in acute ischemic stroke: A historical cohort in Joinville, Brazil Full Text available with Trip Pro

by the NIH stroke scale (p = 0.011). After 90 days, 45% of patients in the IAT group and 27% in the IVT group were independent (0-1 points) according to the modified Rankin scale (adjusted odds ratio: 4.53; 95% CI: 1.22 to 16.75). Symptomatic hemorrhage was diagnosed in 10% of patients in both groups (p = 1.0). The 90-day case-fatality was 39% (32/82) in the IVT group and 26% (8/31) in the IAT group (p = 0.27). In this small cohort, a greater rate of functional independence was achieved in patients (...) Intravenous rtPA versus mechanical thrombectomy in acute ischemic stroke: A historical cohort in Joinville, Brazil Groundbreaking results concerning ischemic stroke (IS) hyperacute treatment worldwide were published in 2014 and 2015. We aimed to compare functional status after 3 months in patients treated with intra-arterial thrombectomy (IAT) and those treated with intravenous thrombolysis (IVT) alone in Joinville, Brazil. From the Joinville Stroke Registry, we extracted and compared all

2016 eNeurologicalSci

187. Relationship Between Language Preference and Intravenous Thrombolysis Among Acute Ischemic Stroke Patients Full Text available with Trip Pro

25 different languages. Multivariable analyses adjusting for other socioeconomic factors showed that non-English-preferring patients were more likely than English-preferring patients to receive IV thrombolysis (OR=1.64; CI=1.09-2.48; P=0.02). However, in models that also included age, sex, and initial NIH Stroke Scale, patients' language preference was no longer significant (OR 1.38; CI=0.88-2.15; P=0.16), but NIH Stroke Scale was strongly associated with receiving IV thrombolysis (OR=1.15 per (...) Relationship Between Language Preference and Intravenous Thrombolysis Among Acute Ischemic Stroke Patients Approximately 20% of the US population primarily speaks a language other than English at home. Yet the effect of language preference on treatment of acute ischemic stroke (AIS) patients remains unknown. We aimed to evaluate the influence of language preference on AIS patients' receipt of intravenous (IV) thrombolysis.We analyzed data from 3894 AIS patients who participated in the American

2016 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

188. Association of dementia with death after ischemic stroke: A two-year prospective study Full Text available with Trip Pro

with death, independent of age, atrial fibrillation, previous stroke and NIH stroke scale. In conclusion, the mortality rate is increased in stroke patients with dementia. Dementia is an important risk factor for death after stroke, independent of age, atrial fibrillation, previous stroke, and the severity of the stroke. (...) Association of dementia with death after ischemic stroke: A two-year prospective study The association between dementia and the risk of death after ischemic stroke was investigated. Neurological, neuropsychological and functional assessments were evaluated in 619 patients with acute ischemic stroke. Dementia was diagnosed at admission and at three months after stroke onset. The patients were scheduled for a two-year follow-up after the index stroke. The Kaplan-Meier survival and Cox

2016 Experimental and therapeutic medicine

189. Utility of EEG measures of brain function in patients with acute stroke Full Text available with Trip Pro

(PLS) modeling, captured extent of acute stroke behavioral deficits and varied in relation to acute brain injury. In 24 patients admitted for acute ischemic stroke, 3 min of resting-state EEG was acquired at bedside, including in the ER and ICU. Traditional quantitative EEG measures (power in a specific lead, in any frequency band) showed a modest association with behavioral deficits [NIH Stroke Scale (NIHSS) score] in bivariate models. However, PLS models of delta or beta power across whole brain (...) correlated strongly with NIHSS score (R(2) = 0.85-0.90) and remained robust when further analyzed with cross-validation models (R(2) = 0.72-0.73). Larger infarct volume was associated with higher delta power, bilaterally; the contralesional findings were not attributable to mass effect, indicating that EEG captures significant information about acute stroke effects not available from MRI. We conclude that 1) dense-array EEG data are feasible as a bedside measure of brain function in patients with acute

2016 Journal of neurophysiology

190. MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)

] Occurrence of an increase in the National Institutes of Health Stroke Scale (NIHSS) score of 4 or more points in the setting of local or remote parenchymal hematoma. Successful recanalization [ Time Frame: within 24 hours of symptom onset ] Defined as modified Thrombolysis in Cerebral Infarction (mTICI) ≥ 2b Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends (...) Inclusion Criteria: Acute ischemic stroke Age 20 years and older Disabling stroke defined as a baseline NIHSS > 5 at the time of arrival Onset (last-seen-well) time to endovascular treatment time < 12 hours Confirmed symptomatic intracranial occlusion, based on CT or MR angiography, at one or more of the following locations: Carotid T/L, M1 MCA, or M1-MCA equivalent (2 or more M2-MCAs) Signed informed consent or appropriate signed deferral of consent where approved Exclusion Criteria: Baseline non

2016 Clinical Trials

191. Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa

Hydroxyurea Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention. Other Name: Hydrea Outcome Measures Go to Primary Outcome Measures : Recurrence of clinically overt stroke, transient ischemic attack or death [ Time Frame: 36 months ] To assess the effectiveness of moderate dose HU therapy at 20 mg/kg/day for secondary stroke prevention when compared to low dose HU therapy at 10 mg/kg/day in children with SCA. Within 30 days after the onset of a first stroke, children (...) 1 to 16 years of age with SCA will be randomized to receive moderate dose HU therapy at 20 mg/kg/day (study group) or low dose HU therapy at 10 mg/kg/day (control group) with monthly follow-up for at least 36 months per participant. Parents will be educated on how to recognize signs and symptoms of a stroke. The rate of stroke recurrence will be measured using standardized neurological examinations (Pediatric NIH Stroke Scale). Secondary Outcome Measures : Incidence of all cause hospitalizations

2016 Clinical Trials

192. Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation. (Abstract)

by NIH Stroke Scale (NIHSS) and Barthel Index (BI) scores. For neuroprotective mechanisms, administration of Rd 4 h after stroke could inhibit ischemia-induced microglial activation, decrease the expression levels of various proinflammatory cytokines, and suppress nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha (IκBα) phosphorylation and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) nuclear translocation. An in vitro proteasome activity (...) Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation. A great deal of attention has been paid to neuroprotective therapies for cerebral ischemic stroke. Our two recent clinical trials showed that ginsenoside Rd (Rd), a kind of monomeric compound extracted from Chinese herbs, Panax ginseng and Panax notoginseng, was safe and efficacious for the treatment of ischemic stroke. In this study, we conducted a pooled analysis of the data

2016 Molecular neurobiology Controlled trial quality: uncertain

193. Study Evaluating the MindMotionPRO for Early Post-stroke Upper-limb Rehabilitation

of stroke symptoms as measured by the NIH stroke scale (NIHSS) [ Time Frame: baseline, 4 weeks, 16 weeks ] Change from Baseline in arm function in daily activities as measured by the Motor Activity Log (MAL) [ Time Frame: baseline, 4 weeks, 16 weeks ] Motivation measured by the Intrinsic Motivation Index (IMI) [ Time Frame: 1 week and 4 weeks ] Other Outcome Measures: Resource utilization: time spent administrating rehabilitation exercises [ Time Frame: 4 weeks ] therapist (physiotherapist or other (...) : Layout table for MeSH terms Stroke Motor Disorders Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Mental Disorders

2016 Clinical Trials

194. Get With the Guidelines-Stroke Registry

Study Completion Date : January 2020 Groups and Cohorts Go to Intervention Details: Other: GWTG Stroke program Evidence based recommended therapies and counseling prior to hospital discharge. Outcome Measures Go to Primary Outcome Measures : NIHSS reported [ Time Frame: 30 days post discharge from hospital ] Percent of ischemic stroke and stroke not otherwise specified patients with a score reported for NIH Stroke Scale In-hospital mortality [ Time Frame: 6 days - mean for length of hospitalization (...) Sample Study Population Patients with a diagnosis of Ischemic stroke or transient ischemic attack, Subarachnoid hemorrhage, Intracerebral hemorrhage, or Stroke not otherwise specified. Criteria Inclusion Criteria: Patients presented with a diagnosis of Ischemic stroke or transient ischemic attack, Subarachnoid hemorrhage, Intracerebral hemorrhage, or Stroke not otherwise specified to the hosptials. Exclusion Criteria: Patients who do not have a diagnosis of Ischemic stroke or transient ischemic

2016 Clinical Trials

195. Prevention of Ischemic Conditions in Non-disabling Stroke/Transient Ischemic Attack With Remote Ischemic Conditioning

[ Time Frame: within 3 months ] the proportion of patients fulfill the treatment Incidence rate of vascular events [ Time Frame: within 3 months ] hemorrhage stroke, myocardial infarction and vascular death Improvements in NIH Stroke Scale [ Time Frame: within1, 3 months ] improvements in NIH Stroke Scale in patients without recurrence or vascular events Improvements in modified Rankin Scale [ Time Frame: within 1, 3 months ] improvements in modified Rankin Scale Scale in patients without recurrence (...) or vascular events Improvements in Barthel Scale [ Time Frame: within 1,3 months ] improvements in Barthel Scale in patients without recurrence or vascular events Other Outcome Measures: Recurrent rate of ischemic stroke/transient ischemic stroke within 1 months [ Time Frame: within 1 months ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding

2016 Clinical Trials

196. Efficacy Study of the LARA Wheelchair System for Subacute Stroke Patients

at the time of enrollment Severe tone in the affected upper extremities (Score ≥ 4 on the Modified Ashworth Spasticity Scale) Severe language problem that would prevent participants from properly understanding instructions Severe reduced level of consciousness Severe aphasia (score of 3 on the NIH stroke scale (question 9)) Severe loss of sensation in stroke-affected upper extremities (Score < 1 on the Nottingham sensory assessment) Currently pregnant Difficulty in understanding or complying (...) exercises for 30 mins/ day. This program of standard arm exercises was developed by an OT at the Rehabilitation Institute of Chicago which consists of graded-difficulty table-supported exercises. This study will have 3 assessment visits: baseline, 3 weeks after therapy or upon discharge from the acute rehabilitation unit if sooner, and a 3-month follow up. Condition or disease Intervention/treatment Phase Cerebrovascular Accident Device: LARA Behavioral: Standard Not Applicable Study Design Go to Layout

2016 Clinical Trials

197. Promoting Recovery Optimization With WALKing Exercise After Stroke

, stent placement or myocardial infarction within past 3 months Musculoskeletal pain that limits activity Inability to communicate with investigators score >1 on question 1b and >0 on question 1c on the NIH Stroke Scale. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (...) -identified data will be deposited in the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (DASH) repository. Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases

2016 Clinical Trials

198. Mechanisms of Walking Recovery After Stroke

, severe claustrophobia) inability to perform mental imagery (time dependent motor imagery screening test [TDMI]) evidence of significant arrhythmia or myocardial ischemia on treadmill ECG stress test, or significant baseline ECG abnormalities that would make an exercise ECG uninterpretable recent (<3 months) cardiopulmonary hospitalization unable to communicate with investigators or correctly answer consent comprehension questions significant ataxia or neglect (score of 2 on NIH stroke scale item 7 (...) Last Update Posted: March 15, 2019 Last Verified: November 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases

2016 Clinical Trials

199. Ventilatory Muscle Training in Stroke

, including: age, gender, race, marital status, education, employment, smoking history, ischemic stroke etiology, stroke severity with NIH Stroke Scale, and stroke location. This information may also be obtained from the RIC electronic medical record. Each subject will undergo a thorough neurologic assessment. Study participants will be randomly assigned to one of two groups: the experimental group with high resistance EMT and the control group with low resistance EMT. The participants will be randomized (...) is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 85 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: History of Ischemic stroke Stroke impairment 8

2016 Clinical Trials

200. Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke

-existing and active major neurological disease Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia A history of significant alcohol or drug abuse in the prior 3 years Advanced liver, kidney, cardiac, or pulmonary disease A terminal medical diagnosis consistent with survival < 1 year Substantial decrease in alertness at the time of randomization, defined as score of 2 on NIH Stroke Scale Pregnancy (...) ClinicalTrials.gov Identifier: Other Study ID Numbers: 2015-10-034 First Posted: May 11, 2016 Last Update Posted: May 11, 2016 Last Verified: May 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Keywords provided by Yun-Hee Kim, Samsung Medical Center: cerebrolysin, stroke, motor function Additional relevant MeSH terms: Layout table for MeSH terms Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>